What type of study is this?

September 10, 2025Neuro-Oncology AdvancesOpen Access

Bevacizumab alternating chemotherapy for improving the survival of patients with recurrent high-grade glioma

View Full Paper

Ask AI

Bookmark

Authors

PLPing-Chuan LiuTaipei Veterans General Hospital CKChao-Yang KuoNational Taipei University of Nursing and Health Science YCYiwei ChenNational Yang Ming Chiao Tung University

Discussion

Member takes

Implication

Retrospective analysis shows bevacizumab alternating chemotherapy enhances survival in patients with high-grade glioma, indicating promising implications for treatment.

Key Points

The bevacizumab alternating chemotherapy regimen significantly improves overall survival in grade 4 gliomas, achieving 29 months versus 19 months.
Median postrecurrence survival for grade 4 glioma patients on the BAC regimen was 16 months compared to 10 months for those on bevacizumab alone.
Data from 95 adult patients were analyzed, highlighting the potential benefits of the BAC approach specifically for IDH-wild-type glioma cases.
The ongoing evaluation of the BAC regimen in future randomized studies is crucial for confirming its advantages and addressing retrospective analysis limitations.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/68c1a41654b1d3bfb60dedd8 https://doi.org/10.1093/noajnl/vdaf157

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows bevacizumab alternating chemotherapy enhances survival in patients with high-grade glioma, indicating promising implications for treatment.

Bevacizumab alternating chemotherapy for improving the survival of patients with recurrent high-grade glioma

Discussion

Member takes

Implication

Key Points

Cite This Study

Bevacizumab alternating chemotherapy for improving the survival of patients with recurrent high-grade glioma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider